Does the media refer more to EYPT or PRE?

In the previous week, Prenetics Global had 6 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 8 mentions for Prenetics Global and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat Prenetics Global's score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prenetics Global 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRE or TRNS?

In the previous week, Prenetics Global had 6 more articles in the media than Transcat. MarketBeat recorded 8 mentions for Prenetics Global and 2 mentions for Transcat. Transcat's average media sentiment score of 1.08 beat Prenetics Global's score of 0.00 indicating that Transcat is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prenetics Global 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Transcat 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CTKB or PRE?

In the previous week, Prenetics Global had 6 more articles in the media than Cytek Biosciences. MarketBeat recorded 8 mentions for Prenetics Global and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.62 beat Prenetics Global's score of 0.00 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prenetics Global 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LAB or PRE?

In the previous week, Prenetics Global had 3 more articles in the media than Standard BioTools. MarketBeat recorded 8 mentions for Prenetics Global and 5 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.58 beat Prenetics Global's score of 0.00 indicating that Standard BioTools is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prenetics Global 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Prenetics Global (PRE) Competitors

$19.25 -1.68 (-8.03%)

Closing price 04:00 PM Eastern

Extended Trading

$19.18 -0.07 (-0.34%)

As of 05:35 PM Eastern

Compare

PRE vs. EYPT, TRNS, FEIM, CTKB, and LAB

Should you buy Prenetics Global stock or one of its competitors? MarketBeat compares Prenetics Global with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prenetics Global include Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Frequency Electronics (FEIM), Cytek Biosciences (CTKB), and Standard BioTools (LAB). These companies are all part of the "measuring and control equipment" industry.

How does Prenetics Global compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Prenetics Global (NASDAQ:PRE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Prenetics Global has higher revenue and earnings than Eyepoint Pharmaceuticals. Prenetics Global is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	32.95	-$231.96M	-$3.50	N/A
Prenetics Global	$92.39M	3.51	-$37.71M	-$4.02	N/A

Prenetics Global has a net margin of -61.33% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Prenetics Global's return on equity of -19.61% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Prenetics Global	-61.33%	-19.61%	-15.33%

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Comparatively, 7.8% of Prenetics Global shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Eyepoint Pharmaceuticals has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market. Comparatively, Prenetics Global has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

In the previous week, Prenetics Global had 6 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 8 mentions for Prenetics Global and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.93 beat Prenetics Global's score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prenetics Global	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eyepoint Pharmaceuticals currently has a consensus price target of $31.80, indicating a potential upside of 157.91%. Prenetics Global has a consensus price target of $32.33, indicating a potential upside of 67.97%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Prenetics Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Eyepoint Pharmaceuticals beats Prenetics Global on 10 of the 17 factors compared between the two stocks.

How does Prenetics Global compare to Transcat?

Prenetics Global (NASDAQ:PRE) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Prenetics Global has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Transcat has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

Prenetics Global presently has a consensus price target of $32.33, suggesting a potential upside of 67.97%. Transcat has a consensus price target of $105.33, suggesting a potential upside of 19.64%. Given Prenetics Global's higher possible upside, equities research analysts plainly believe Prenetics Global is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Transcat has a net margin of 1.62% compared to Prenetics Global's net margin of -61.33%. Transcat's return on equity of 5.84% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-61.33%	-19.61%	-15.33%
Transcat	1.62%	5.84%	3.78%

25.0% of Prenetics Global shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 7.8% of Prenetics Global shares are owned by insiders. Comparatively, 2.8% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Prenetics Global had 6 more articles in the media than Transcat. MarketBeat recorded 8 mentions for Prenetics Global and 2 mentions for Transcat. Transcat's average media sentiment score of 1.08 beat Prenetics Global's score of 0.00 indicating that Transcat is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prenetics Global	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Transcat	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Transcat has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$92.39M	3.51	-$37.71M	-$4.02	N/A
Transcat	$331.88M	2.48	$5.38M	$0.58	151.79

Summary

Transcat beats Prenetics Global on 12 of the 17 factors compared between the two stocks.

How does Prenetics Global compare to Frequency Electronics?

Frequency Electronics (NASDAQ:FEIM) and Prenetics Global (NASDAQ:PRE) are both small-cap measuring and control equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Frequency Electronics has a net margin of 10.78% compared to Prenetics Global's net margin of -61.33%. Frequency Electronics' return on equity of 12.69% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Frequency Electronics	10.78%	12.69%	7.84%
Prenetics Global	-61.33%	-19.61%	-15.33%

In the previous week, Prenetics Global had 7 more articles in the media than Frequency Electronics. MarketBeat recorded 8 mentions for Prenetics Global and 1 mentions for Frequency Electronics. Frequency Electronics' average media sentiment score of 0.93 beat Prenetics Global's score of 0.00 indicating that Frequency Electronics is being referred to more favorably in the media.

Company	Overall Sentiment
Frequency Electronics	Positive
Prenetics Global	Neutral

Frequency Electronics has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Prenetics Global has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Frequency Electronics currently has a consensus target price of $43.67, suggesting a potential downside of 34.46%. Prenetics Global has a consensus target price of $32.33, suggesting a potential upside of 67.97%. Given Prenetics Global's higher probable upside, analysts clearly believe Prenetics Global is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

58.6% of Frequency Electronics shares are owned by institutional investors. Comparatively, 25.0% of Prenetics Global shares are owned by institutional investors. 28.0% of Frequency Electronics shares are owned by insiders. Comparatively, 7.8% of Prenetics Global shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Frequency Electronics has higher earnings, but lower revenue than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Frequency Electronics	$69.81M	9.39	$23.69M	$0.75	88.84
Prenetics Global	$92.39M	3.51	-$37.71M	-$4.02	N/A

Summary

Frequency Electronics beats Prenetics Global on 13 of the 17 factors compared between the two stocks.

How does Prenetics Global compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Prenetics Global (NASDAQ:PRE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

In the previous week, Prenetics Global had 6 more articles in the media than Cytek Biosciences. MarketBeat recorded 8 mentions for Prenetics Global and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.62 beat Prenetics Global's score of 0.00 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prenetics Global	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytek Biosciences has a net margin of -36.25% compared to Prenetics Global's net margin of -61.33%. Cytek Biosciences' return on equity of -10.07% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Prenetics Global	-61.33%	-19.61%	-15.33%

Cytek Biosciences has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Prenetics Global has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 25.0% of Prenetics Global shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by company insiders. Comparatively, 7.8% of Prenetics Global shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Prenetics Global has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.60	-$66.54M	-$0.57	N/A
Prenetics Global	$92.39M	3.51	-$37.71M	-$4.02	N/A

Cytek Biosciences presently has a consensus target price of $5.69, suggesting a potential upside of 40.43%. Prenetics Global has a consensus target price of $32.33, suggesting a potential upside of 67.97%. Given Prenetics Global's stronger consensus rating and higher probable upside, analysts clearly believe Prenetics Global is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cytek Biosciences beats Prenetics Global on 9 of the 15 factors compared between the two stocks.

How does Prenetics Global compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and Prenetics Global (NASDAQ:PRE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Standard BioTools has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Prenetics Global has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 25.0% of Prenetics Global shares are held by institutional investors. 26.8% of Standard BioTools shares are held by company insiders. Comparatively, 7.8% of Prenetics Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Prenetics Global had 3 more articles in the media than Standard BioTools. MarketBeat recorded 8 mentions for Prenetics Global and 5 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.58 beat Prenetics Global's score of 0.00 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prenetics Global	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Standard BioTools has a net margin of 73.46% compared to Prenetics Global's net margin of -61.33%. Standard BioTools' return on equity of -8.18% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	73.46%	-8.18%	-6.43%
Prenetics Global	-61.33%	-19.61%	-15.33%

Prenetics Global has higher revenue and earnings than Standard BioTools. Prenetics Global is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	4.03	-$74.90M	$0.20	4.41
Prenetics Global	$92.39M	3.51	-$37.71M	-$4.02	N/A

Standard BioTools presently has a consensus price target of $1.35, indicating a potential upside of 53.22%. Prenetics Global has a consensus price target of $32.33, indicating a potential upside of 67.97%. Given Prenetics Global's stronger consensus rating and higher probable upside, analysts clearly believe Prenetics Global is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Standard BioTools beats Prenetics Global on 10 of the 16 factors compared between the two stocks.

Get Prenetics Global News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRE vs. The Competition

Export

Metric	Prenetics Global	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$353.17M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-4.79	18.83	24.65	23.63
Price / Sales	3.51	290.84	500.87	105.21
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	2.08	8.00	10.43	6.70
Net Income	-$37.71M	$23.89M	$3.56B	$337.26M
7 Day Performance	-7.59%	-3.49%	-1.39%	-1.41%
1 Month Performance	19.12%	1.03%	0.86%	1.15%
1 Year Performance	140.63%	34.39%	19.42%	22.61%

Prenetics Global Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRE Prenetics Global	2.3187 of 5 stars	$19.25 -8.0%	$32.33 +68.0%	+171.1%	$353.17M	$92.39M	N/A	1	News Coverage Earnings Report Gap Down
EYPT Eyepoint Pharmaceuticals	2.9241 of 5 stars	$12.53 -4.7%	$31.80 +153.8%	+31.8%	$1.10B	$7.61M	N/A	120
TRNS Transcat	3.4882 of 5 stars	$90.56 +2.8%	$105.33 +16.3%	+17.4%	$822.82M	$331.88M	156.14	1,413	Positive News
FEIM Frequency Electronics	1.5797 of 5 stars	$72.16 -0.6%	$43.67 -39.5%	+261.8%	$714.23M	$69.81M	96.21	200
CTKB Cytek Biosciences	2.1184 of 5 stars	$4.19 -1.2%	$5.69 +35.7%	+16.0%	$547.57M	$204.17M	N/A	500	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRE) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prenetics Global (PRE) Competitors

PRE vs. EYPT, TRNS, FEIM, CTKB, and LAB

How does Prenetics Global compare to Eyepoint Pharmaceuticals?

Summary

How does Prenetics Global compare to Transcat?

Summary

How does Prenetics Global compare to Frequency Electronics?

Summary

How does Prenetics Global compare to Cytek Biosciences?

Summary

How does Prenetics Global compare to Standard BioTools?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRE vs. The Competition

Prenetics Global Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prenetics Global (PRE) Competitors

PRE vs. EYPT, TRNS, FEIM, CTKB, and LAB

How does Prenetics Global compare to Eyepoint Pharmaceuticals?

Which has preferable earnings & valuation, EYPT or PRE?

Is EYPT or PRE more profitable?

Do institutionals and insiders believe in EYPT or PRE?

Which has more risk & volatility, EYPT or PRE?

Does the media refer more to EYPT or PRE?

Do analysts recommend EYPT or PRE?

Summary

How does Prenetics Global compare to Transcat?

Which has more risk & volatility, PRE or TRNS?

Do analysts recommend PRE or TRNS?

Is PRE or TRNS more profitable?

Do insiders and institutionals hold more shares of PRE or TRNS?

Does the media prefer PRE or TRNS?

Which has better earnings & valuation, PRE or TRNS?

Summary

How does Prenetics Global compare to Frequency Electronics?

Is FEIM or PRE more profitable?

Does the media refer more to FEIM or PRE?

Which has more volatility and risk, FEIM or PRE?

Do analysts prefer FEIM or PRE?

Do institutionals and insiders have more ownership in FEIM or PRE?

Which has better earnings and valuation, FEIM or PRE?

Summary

How does Prenetics Global compare to Cytek Biosciences?

Does the media refer more to CTKB or PRE?

Is CTKB or PRE more profitable?

Which has more risk & volatility, CTKB or PRE?

Do institutionals and insiders hold more shares of CTKB or PRE?

Which has preferable earnings & valuation, CTKB or PRE?

Do analysts recommend CTKB or PRE?

Summary

How does Prenetics Global compare to Standard BioTools?

Which has more risk and volatility, LAB or PRE?

Do institutionals and insiders have more ownership in LAB or PRE?

Does the media refer more to LAB or PRE?

Is LAB or PRE more profitable?

Which has better valuation and earnings, LAB or PRE?

Do analysts rate LAB or PRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRE vs. The Competition

Prenetics Global Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools